Assessing GLP-1 RAs and GIP-GLP-1 RAs: The Latest Data for Benefits Beyond Glycemic Control – Post Survey

Now, how confident are you in your ability to explain to patients with T2D the differences in mechanisms of action, safety, and efficacy on HbA1c levels of GLP-1 RA and GIP/GLP-1 RA incretin therapies?(Required)

Not at all confident

Somewhat confident

Confident

Very confident

Which of the following outcomes was noted in the SURMOUNT studies of tirzepatide for the treatment of obesity and related complications?(Required)

Tirzepatide had no appreciable effect on lipid parameters

More than 90% of patients achieved a ≥ 15% weight loss after 24 weeks

Patients with obesity and diabetes lose less weight than patients with obesity alone

Drop in HbA1c paralleled weight loss, with maximum lowering of HbA1c and weight loss occurring after 60 weeks of therapy

Assessing GLP-1 RAs and GIP-GLP-1 RAs: The Latest Data for Benefits Beyond Glycemic Control – Post Survey

Join our newsletter